Biomimetic membrane-coated metal nanoplatforms for enhanced BBB penetration and targeted glioblastoma therapy.

Authors

Danyang Yun, Lizhen Mu, Juan Liu, Cuiping Li, Siyuan Zhao, Qiaoli Zhai, Huan Sun, Xin Wu, Kourong Shi, Wei Fan

Published in

International journal of pharmaceutics: X. Volume 12. Pages 100612. Epub Jul 13, 2026.

Abstract

Glioblastoma (GBM) is characterized by highly infiltrative growth, pronounced heterogeneity, and adaptive plasticity, leading to poor prognosis and frequent recurrence. Tumor dissemination beyond imaging-defined margins, together with the blood-brain barrier (BBB), heterogeneous blood-brain tumor barrier (BBTB), and immunosuppressive tumor microenvironment, severely limits therapeutic efficacy. Metal-based nanomaterials have emerged as promising theranostic platforms owing to their multifunctionality, enabling multimodal imaging and photothermal, photodynamic, and chemodynamic therapies. However, their clinical translation is constrained by rapid clearance, inadequate BBB/BBTB penetration, and limited intratumoral distribution. Cell membrane-coated metal nanoplatforms have recently emerged as an effective biomimetic strategy to overcome these barriers. By incorporating membranes derived from red blood cells, cancer cells, or immune cells, these systems achieve immune evasion, prolonged circulation, enhanced BBB penetration, and improved tumor targeting. Moreover, recent advances demonstrate their ability to programmably regulate tumor-immune interactions and respond to the tumor microenvironment, shifting nanomedicine from passive delivery toward adaptive theranostic platforms. This review summarizes recent advances in membrane-coated metal nanoplatforms for GBM, highlighting their design principles, biological mechanisms, and applications in synergistic therapy, while discussing their translational potential and the remaining challenges for clinical application.

PMID:
42502435
Bibliographic data and abstract were imported from PubMed on 26 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.